North America Metastatic Cancer Drugs Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)

No. of Pages: 160    |    Report Code: BMIRE00025361    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Metastatic Cancer Drugs Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Metastatic Cancer Drugs Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Growth Drivers
5.2 Market Opportunities
5.3 Future Trends
5.4 Impact of Drivers and Restraints

6. North America Metastatic Cancer Drugs Market Regional Analysis

6.1 North America Metastatic Cancer Drugs Market Overview
6.2 North America Metastatic Cancer Drugs Market Revenue 2019-2028 (US$ Million)
6.3 North America Metastatic Cancer Drugs Market Forecast Analysis

7. North America Metastatic Cancer Drugs Market Analysis – by Cancer Type

7.1 Breast Cancer
  • 7.1.1 Overview
  • 7.1.2 Breast Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Lung Cancer
  • 7.2.1 Overview
  • 7.2.2 Lung Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Liver Cancer
  • 7.3.1 Overview
  • 7.3.2 Liver Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Hematological Cancer
  • 7.4.1 Overview
  • 7.4.2 Hematological Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Brain Cancer
  • 7.5.1 Overview
  • 7.5.2 Brain Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Prostate Cancer
  • 7.6.1 Overview
  • 7.6.2 Prostate Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Pancreatic Cancer
  • 7.7.1 Overview
  • 7.7.2 Pancreatic Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Metastatic Cancer Drugs Market Analysis – by Route of Administration

8.1 Intravenous and Intramuscular
  • 8.1.1 Overview
  • 8.1.2 Intravenous and Intramuscular: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Metastatic Cancer Drugs Market Analysis – by Drug Class

9.1 HER2 Inhibitors
  • 9.1.1 Overview
  • 9.1.2 Intravenous and Intramuscular: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Immune Checkpoint Inhibitors
  • 9.2.1 Overview
  • 9.2.2 Intravenous and Intramuscular: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
9.3 PARP Inhibitors
  • 9.3.1 Overview
  • 9.3.2 Intravenous and Intramuscular: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Kinase Inhibitors
  • 9.4.1 Overview
  • 9.4.2 Intravenous and Intramuscular: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Metastatic Cancer Drugs Market – North America Analysis

10.1 North America
  • 10.1.1 North America Metastatic Cancer Drugs Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 North America Metastatic Cancer Drugs Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 10.1.1.1.2 US: North America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 10.1.1.1.3 US: North America Metastatic Cancer Drugs Market Breakdown, by Drug Class
  • 10.1.1.2 Canada: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 10.1.1.2.2 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 10.1.1.2.3 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Drug Class
  • 10.1.1.3 Mexico : North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 10.1.1.3.2 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 10.1.1.3.3 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Drug Class

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Metastatic Cancer Drugs Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AbbVie Inc.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Amgen Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Bristol-Myers Squibb Company
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 F. HOFFMANN-LA ROCHE LTD.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Novartis AG
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Astrazeneca
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Eli Lilly and Company
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 MERCK KGaA
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Johnson and Johnson Services, Inc.
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

  1. AbbVie Inc.                                                                                                        
  2. Amgen Inc.                                                                                                         
  3. Bristol-Myers Squibb Company                                                                 
  4. F. HOFFMANN-LA ROCHE LTD.                                                                   
  5. Novartis AG                                                                                                       
  6. Astrazeneca                                                                                                      
  7. Eli Lilly and Company                                                                                     
  8. MERCK KGaA                                                                                                    
  9. Pfizer Inc. (Arena Pharmaceutical GmbH)                                             
  10. Johnson and Johnson Services, Inc.
north-america-metastatic-cancer-drugs-market